Maslow Joel N
GeneOne Life Science, Inc., Seoul 06060, Korea.
Department of Medicine, Morristown Medical Center, Morristown, NJ 07960, USA.
Trop Med Infect Dis. 2019 Jul 14;4(3):104. doi: 10.3390/tropicalmed4030104.
Zika virus is an emergent pathogen that gained significant importance during the epidemic in South and Central America as unusual and alarming complications of infection were recognized. Although initially considered a self-limited benign infection, a panoply of neurologic complications were recognized including a Guillain-Barré-like syndrome and in-utero fetal infection causing microcephaly, blindness, and other congenital neurologic complications. Numerous Zika virus vaccines were developed, with nine different vaccines representing five different platforms entered into clinical trials, one progressing to Phase II. Here we review the current landscape and challenges confronting Zika virus vaccine development.
寨卡病毒是一种新出现的病原体,在南美洲和中美洲的疫情期间,由于认识到感染会出现异常且令人担忧的并发症,它变得极为重要。尽管最初被认为是一种自限性的良性感染,但后来认识到一系列神经系统并发症,包括一种格林-巴利综合征样综合征以及子宫内胎儿感染导致小头畸形、失明和其他先天性神经系统并发症。人们研发了许多寨卡病毒疫苗,有九种不同疫苗代表五个不同平台进入了临床试验,其中一种进入了二期试验。在此,我们综述了寨卡病毒疫苗研发目前面临的情况和挑战。